Single User License
INR 135120
Site License
INR 270240
Corporate User License
INR 405360

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Drug Addiction-Pipeline Review, H1 2015

Drug Addiction-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Drug Addiction-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Drug Addiction-Pipeline Review, H1 2015', provides an overview of the Drug Addiction's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Drug Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Drug Addiction and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Drug Addiction

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Drug Addiction and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Drug Addiction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Drug Addiction pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Drug Addiction

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Drug Addiction pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Drug Addiction Overview 9

Therapeutics Development 10

Pipeline Products for Drug Addiction-Overview 10

Pipeline Products for Drug Addiction-Comparative Analysis 11

Drug Addiction-Therapeutics under Development by Companies 12

Drug Addiction-Therapeutics under Investigation by Universities/Institutes 13

Drug Addiction-Pipeline Products Glance 14

Clinical Stage Products 14

Early Stage Products 15

Unknown Stage Products 16

Drug Addiction-Products under Development by Companies 17

Drug Addiction-Products under Investigation by Universities/Institutes 18

Drug Addiction-Companies Involved in Therapeutics Development 19

Addex Therapeutics Ltd 19

Aphios Corporation 20

Curemark, LLC 21

Embera NeuroTherapeutics, Inc. 22

Gilead Sciences, Inc. 23

Immunovaccine, Inc. 24

Kyorin Pharmaceutical Co., Ltd. 25

Lightlake Therapeutics Inc. 26

Omeros Corporation 27

Rottapharm SpA 28

Teva Pharmaceutical Industries Limited 29

Drug Addiction-Therapeutics Assessment 30

Assessment by Monotherapy Products 30

Assessment by Combination Products 31

Assessment by Target 32

Assessment by Mechanism of Action 34

Assessment by Route of Administration 36

Assessment by Molecule Type 38

Drug Profiles 40

(oxazepam + metyrapone)-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

ADX-71441-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

ADX-88178-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

cannabidiol-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

CM-1212-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

CR-5542 Series-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

dronabinol-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Drug for Dependence-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

GS-6637-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

ibudilast-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

LT-22-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

MC-100093-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

Methoxycoronaridine-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

OMS-527-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

Small Molecule for Drug Addiction-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

Small Molecule to Activate Kappa Opioid Receptor for CNS-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

Small Molecule to Inhibit BRD for Cocaine Dependence-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

Small Molecule to Inhibit Kappa Opioid Receptor for CNS-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

Small Molecules to Activate Delta Opioid Receptor for Immunology, CNS and Metabolic Disorders-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

Small Molecules to Inhibit CB1 Receptor for Cannabinoid Abuse and Drug Addiction-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

Small Molecules to Inhibit DAT and SERT for CNS Disorders-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

Small Molecules to Modulate 5HT2 for CNS and Metabolic Disorders-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

TV-1380-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

Vaccine for Cocaine Addiction-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

Vaccine for Cocaine Addiction-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

Vaccine for Methamphetamine Addiction-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

Drug Addiction-Recent Pipeline Updates 69

Drug Addiction-Dormant Projects 78

Drug Addiction-Discontinued Products 80

Drug Addiction-Product Development Milestones 81

Featured News & Press Releases 81

Apr 10, 2015: HRA Pharma Closes Investment in Embera NeuroTherapeutics to Advance Development of Novel Therapies for Addiction 81

Sep 23, 2014: Savant HWP Confirms Initiation of a Human Safety Trial for 18-MC, a Potential Anti-Addiction Therapy 81

Aug 09, 2013: Curemark wins patent for CM-1212 to treat drug, alcohol addiction 82

Jun 18, 2013: MediciNova Announces Presentation Of Preliminary Results From Phase Ib Study Of MN-166 In Methamphetamine Addiction At 75th Annual Meeting Of CPDD 82

Feb 25, 2013: MediciNova's MN-166 Receives Fast Track Designation From FDA For Treatment Of Methamphetamine Dependence 83

Jan 18, 2013: Research team including Dr Gianluca Baio funded by the MRC 84

Jan 03, 2013: MediciNova Provides Development Update On MN-166 85

Sep 04, 2012: NIH Funds UCLA Phase II Study Of MediciNova's MN-166 For Treament Of Methamphetamine Addiction 85

Jan 04, 2011: Scripps Research and Cornell Scientists Create Novel Vaccine that Produces Strong Immunity Against Cocaine High 87

Appendix 89

Methodology 89

Coverage 89

Secondary Research 89

Primary Research 89

Expert Panel Validation 89

Contact Us 89

Disclaimer 90

List of Tables

Number of Products under Development for Drug Addiction, H1 2015 10

Number of Products under Development for Drug Addiction-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Number of Products under Investigation by Universities/Institutes, H1 2015 13

Comparative Analysis by Clinical Stage Development, H1 2015 14

Comparative Analysis by Early Stage Development, H1 2015 15

Comparative Analysis by Unknown Stage Development, H1 2015 16

Products under Development by Companies, H1 2015 17

Products under Investigation by Universities/Institutes, H1 2015 18

Drug Addiction-Pipeline by Addex Therapeutics Ltd, H1 2015 19

Drug Addiction-Pipeline by Aphios Corporation, H1 2015 20

Drug Addiction-Pipeline by Curemark, LLC, H1 2015 21

Drug Addiction-Pipeline by Embera NeuroTherapeutics, Inc., H1 2015 22

Drug Addiction-Pipeline by Gilead Sciences, Inc., H1 2015 23

Drug Addiction-Pipeline by Immunovaccine, Inc., H1 2015 24

Drug Addiction-Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2015 25

Drug Addiction-Pipeline by Lightlake Therapeutics Inc., H1 2015 26

Drug Addiction-Pipeline by Omeros Corporation, H1 2015 27

Drug Addiction-Pipeline by Rottapharm SpA, H1 2015 28

Drug Addiction-Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 29

Assessment by Monotherapy Products, H1 2015 30

Assessment by Combination Products, H1 2015 31

Number of Products by Stage and Target, H1 2015 33

Number of Products by Stage and Mechanism of Action, H1 2015 35

Number of Products by Stage and Route of Administration, H1 2015 37

Number of Products by Stage and Molecule Type, H1 2015 39

Drug Addiction Therapeutics-Recent Pipeline Updates, H1 2015 69

Drug Addiction-Dormant Projects, H1 2015 78

Drug Addiction-Dormant Projects (Contd..1), H1 2015 79

Drug Addiction-Discontinued Products, H1 2015 80

List of Figures

Number of Products under Development for Drug Addiction, H1 2015 10

Number of Products under Development for Drug Addiction-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Number of Products under Investigation by Universities/Institutes, H1 2015 13

Comparative Analysis by Clinical Stage Development, H1 2015 14

Comparative Analysis by Early Stage Products, H1 2015 15

Assessment by Monotherapy Products, H1 2015 30

Number of Products by Stage and Top 10 Targets, H1 2015 32

Number of Products by Top 10 Mechanism of Actions, H1 2015 34

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 34

Number of Products by Top 10 Routes of Administration, H1 2015 36

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 37

Number of Products by Top 10 Molecule Types, H1 2015 38

Number of Products by Stage and Top 10 Molecule Types, H1 2015 39

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Addex Therapeutics Ltd 19

Aphios Corporation 20

Curemark, LLC 21

Embera NeuroTherapeutics, Inc. 22

Gilead Sciences, Inc. 23

Immunovaccine, Inc. 24

Kyorin Pharmaceutical Co., Ltd. 25

Lightlake Therapeutics Inc. 26

Omeros Corporation 27

Rottapharm SpA 28

Drug Addiction Therapeutic Products under Development, Key Players in Drug Addiction Therapeutics, Drug Addiction Pipeline Overview, Drug Addiction Pipeline, Drug Addiction Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com